Trial reportGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology2014
The rate of high ovarian response in women identified at risk by a high serum AMH level is influenced by the type of gonadotropin.
Trial report in Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Luteinizing hormone activity in ovarian stimulation: comparative efficacy and safety of gonadotropinsFrontiers in endocrinology · 2026Pooled it
- Controlled ovarian stimulation protocols for assisted reproduction: a network meta-analysis.The Cochrane database of systematic reviews · 2025Pooled it
- The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review.Advances in therapy · 2020Pooled it
- Article
- Pilot Trial to Individualize the Dose of Follitropin Delta in Oocyte Donors: REKO15.Journal of clinical medicine · 2025Article
- Anti-Müllerian hormone as a predictor of the number of oocytes obtained during in vitro fertilization treatments.JBRA assisted reproduction · 2024Observational
- Oocyte stimulation parameters influence the number and proportion of mature oocytes retrieved in assisted reproductive technology cycles.Journal of assisted reproduction and genetics · 2021Article
- Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany.Reproductive biology and endocrinology : RB&E · 2021Article
- GnRH triggering may improve euploidy and live birth rate in hyper-responders: a retrospective cohort study.Journal of assisted reproduction and genetics · 2020Article
- A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF.Human reproduction open · 2019Article
- Live birth rates in the different combinations of the Bologna criteria poor ovarian responders: a validation study.Journal of assisted reproduction and genetics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim was to compare ovarian response and clinical outcome of potential high-responders after stimulation with highly purified menotropin (HP-hMG) or recombinant follicle-stimulating hormone (rFSH) for in vitro fertilisation/intracytoplasmic sperm injection. Retrospective analysis was performed on data collected in two randomized controlled trials, one conducted following a long GnRH agonist protocol and the other with an antagonist protocol. Potential high-responders (n = 155 and n = 188 in the agonist and antagonist protocol, respectively) were defined as having an initial anti-Müllerian hormone (AMH) value >75th percentile (5.2 ng/ml). In both protocols, HP-hMG stimulation in women in the high AMH category was associated with a significantly lower occurrence of high response (≥15 oocytes retrieved) than rFSH stimulation; 33% versus 51% (p = 0.025) and 31% versus 49% (p = 0.015) in the long agonist and antagonist protocol, respectively. In the potential high-responder women, trends for improved live birth rate were observed with HP-hMG compared with rFSH (long agonist protocol: 33% versus 20%, p = 0.074; antagonist protocol: 34% versus 23%, p = 0.075; overall population: 34% versus 22%, p = 0.012). In conclusion, the type of gonadotropin used for ovarian stimulation influences high-response rates and potentially clinical outcome in women identified as potential high-responders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.